The Supreme Court of the United States granted review in two cases this afternoon:
Mutual Pharmaceutical Co. v. Bartlett, No. 12-142: Whether the First Circuit erred when it created a circuit split and held that federal law does not preempt state law design-defect claims targeting generic pharmaceutical products because the conceded conflict between such claims and the federal laws governing generic pharmaceutical design allegedly can be avoided if the makers of generic pharmaceuticals simply stop making their products.
Association for Molecular Pathology v. Myriad Genetics, Inc., No. 12-398: Are human genes patentable?